1. Home
  2. EWTX vs NWN Comparison

EWTX vs NWN Comparison

Compare EWTX & NWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • NWN
  • Stock Information
  • Founded
  • EWTX 2017
  • NWN 1859
  • Country
  • EWTX United States
  • NWN United States
  • Employees
  • EWTX N/A
  • NWN N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • NWN Oil/Gas Transmission
  • Sector
  • EWTX Health Care
  • NWN Utilities
  • Exchange
  • EWTX Nasdaq
  • NWN Nasdaq
  • Market Cap
  • EWTX 1.6B
  • NWN 1.7B
  • IPO Year
  • EWTX 2021
  • NWN N/A
  • Fundamental
  • Price
  • EWTX $14.95
  • NWN $44.05
  • Analyst Decision
  • EWTX Buy
  • NWN Buy
  • Analyst Count
  • EWTX 10
  • NWN 2
  • Target Price
  • EWTX $37.90
  • NWN $48.00
  • AVG Volume (30 Days)
  • EWTX 957.0K
  • NWN 223.2K
  • Earning Date
  • EWTX 11-06-2025
  • NWN 11-11-2025
  • Dividend Yield
  • EWTX N/A
  • NWN 4.45%
  • EPS Growth
  • EWTX N/A
  • NWN 17.48
  • EPS
  • EWTX N/A
  • NWN 2.58
  • Revenue
  • EWTX N/A
  • NWN $1,238,288,000.00
  • Revenue This Year
  • EWTX N/A
  • NWN $17.95
  • Revenue Next Year
  • EWTX N/A
  • NWN $5.66
  • P/E Ratio
  • EWTX N/A
  • NWN $17.09
  • Revenue Growth
  • EWTX N/A
  • NWN 8.40
  • 52 Week Low
  • EWTX $10.60
  • NWN $38.03
  • 52 Week High
  • EWTX $38.12
  • NWN $45.07
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 49.70
  • NWN 63.69
  • Support Level
  • EWTX $14.85
  • NWN $43.87
  • Resistance Level
  • EWTX $15.84
  • NWN $44.96
  • Average True Range (ATR)
  • EWTX 1.08
  • NWN 0.67
  • MACD
  • EWTX -0.06
  • NWN 0.01
  • Stochastic Oscillator
  • EWTX 31.42
  • NWN 72.81

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

Share on Social Networks: